579. Design and Immunogenicity of a Pan-SARS-CoV-2 Synthetic DNA Vaccine

Abstract Background First-generation COVID-19 vaccines are matched to spike protein of the Wuhan-H1 (WT) strain. Convalescent and vaccinee samples show reduced neutralization of SARS-CoV-2 variants of concern (VOC). Next generation DNA vaccines could be matched to single variants or synthetically designed for broader coverage of multiple VOCs. Methods The synthetic consensus (SynCon®) sequence for INO-4802 SARS-CoV-2 spike with focused RBD changes and dual proline mutations was codon-optimized (Figure 1). Sequences for wild-type (pWT) and B.1.351 (pB.1.351) were similarly optimized. Immunogenicity was evaluated in BALB/c mice. Pre-clinical efficacy was assessed in the Syrian Hamster model. Figure 1. Design Strategy for INO-4802 Results INO-4802 induced potent neutralizing antibody responses against WT, B.1.1.7, P.1, and B.1.351 VOC in a murine model. pWT vaccinated animals showed a 3-fold reduction in mean neutralizing ID50 for the B.1.351 pseudotyped virus. INO-4802 immunized animals had significantly higher (p = 0.0408) neutralizing capacity (mean ID50 816.16). ID50 of pB.1.351 serum was reduced 7-fold for B.1.1.7 and significantly lower (p = 0.0068) than INO-4802 (317.44). INO-4802 neutralized WT (548.28) comparable to pWT. INO-4802 also neutralized P.1 (1026.6) (Figure 2). pWT, pB.1.351 or INO-4802 induced similar T-cell responses against all variants. INO-4802 skewed towards a TH1-response. All hamsters vaccinated with INO-4802 or pB.1.351 were protected from weight loss after B.1.351 live virus challenge. 4/6 pWT immunized hamsters were completely protected. pWT immunized hamsters neutralized WT (1090) but not B.1.351 (39.16). INO-4802 neutralized both WT (672.2) and B.1.351 (1121) (Figure 3). We observed higher increase of binding titers following heterologous boost with INO-4802 (3.6 – 4.4 log2-fold change) than homologous boost with pWT (2.0 – 2.4 log2 fold change) (Figure 4). Figure 2. INO-4802 Induces Functional Humoral Immune Response Against SARS-CoV-2 Variants of Concern Figure 3. INO-4802 Protects Hamsters Against Challenge With B.1.351 Live Virus Figure 4. Heterologous Boost with INO-4802 Induces Humoral Immune Response Against SARS-CoV-2 Variants Conclusion Vaccines matching single VOCs, like pB.1.351 and pWT, elicit responses against the matched antigen but have reduced cross-reactivity. Presenting a pan-SARS-CoV-2 approach, INO-4802 may offer substantial advantages in terms of cross-strain protection, reduced susceptibility to escape mutants and non-restricted geographical use. Disclosures Katherine Schultheis, MSc, Inovio Pharmaceuticals (Employee) Charles C. Reed, PhD, Inovio Pharmaceuticals (Employee, Shareholder) Viviane M. Andrade, PhD, Inovio Pharmaceuticals Inc. (Employee) Richa Kalia, MS, Inovio Pharmaceuticals (Employee, Other Financial or Material Support, I have stock options with Inovio Pharmaceuticals as an employee.) Jared Tur, PhD, Inovio (Employee) Blake Schouest, PhD, Inovio Pharmaceuticals (Employee) Dustin Elwood, PhD, Inovio Pharmaceuticals (Employee) Arthur Doan, n/a, Inovio (Employee) Patrick Pezzoli, BS, Inovio (Employee) Dinah Amante, BS, Inovio (Employee) David Weiner, PhD, Inovio (Board Member, Grant/Research Support, Shareholder, I serve on the SAB in addition to the above activities) J Joseph Kim, PhD, Inovio (Employee) Laurent Humeau, PhD, Inovio Pharmaceuticals (Employee) Stephanie Ramos, PhD, Inovio Pharmaceuticals (Employee) Trevor R. F. Smith, PhD, Inovio (Employee, Shareholder) Kate Broderick, PhD, Inovio (Employee).

Download Full-text

Recombinant Mycobacterium paragordonae Expressing SARS-CoV-2 Receptor-Binding Domain as a Vaccine Candidate Against SARS-CoV-2 Infections

Frontiers in Immunology ◽

10.3389/fimmu.2021.712274 ◽

2021 ◽

Vol 12 ◽

Author(s):

Byoung-Jun Kim ◽

Hyein Jeong ◽

Hyejun Seo ◽

Mi-Hyun Lee ◽

Hyun Mu Shin ◽

...

Keyword(s):

Immune Response ◽

Single Dose ◽

Immune Responses ◽

Receptor Binding ◽

Humoral Immune Response ◽

Vaccine Candidate ◽

Binding Domain ◽

Receptor Binding Domain ◽

Live Virus ◽

Humoral Immune

At present, concerns that the recent global emergence of SARS-CoV-2 variants could compromise the current vaccines have been raised, highlighting the urgent demand for new vaccines capable of eliciting T cell-mediated immune responses, as well as B cell-mediated neutralizing antibody production. In this study, we developed a novel recombinant Mycobacterium paragordonae expressing the SARS-CoV-2 receptor-binding domain (RBD) (rMpg-RBD-7) that is capable of eliciting RBD-specific immune responses in vaccinated mice. The potential use of rMpg-RBD-7 as a vaccine for SARS-CoV-2 infections was evaluated in in vivo using mouse models of two different modules, one for single-dose vaccination and the other for two-dose vaccination. In a single-dose vaccination model, we found that rMpg-RBD-7 versus a heat-killed strain could exert an enhanced cell-mediated immune (CMI) response, as well as a humoral immune response capable of neutralizing the RBD and ACE2 interaction. In a two-dose vaccination model, rMpg-RBD-7 in a two-dose vaccination could also exert a stronger CMI and humoral immune response to neutralize SARS-CoV-2 infections in pseudoviral or live virus infection systems, compared to single dose vaccinations of rMpg-RBD or two-dose RBD protein immunization. In conclusion, our data showed that rMpg-RBD-7 can lead to an enhanced CMI response and humoral immune responses in mice vaccinated with both single- or two-dose vaccination, highlighting its feasibility as a novel vaccine candidate for SARS-CoV-2. To the best of our knowledge, this study is the first in which mycobacteria is used as a delivery system for a SARS-CoV-2 vaccine.

Download Full-text

Robust and durable serological response following pediatric SARS-CoV-2 infection

Nature Communications ◽

10.1038/s41467-021-27595-9 ◽

2022 ◽

Vol 13 (1) ◽

Author(s):

Hanna Renk ◽

Alex Dulovic ◽

Alina Seidel ◽

Matthias Becker ◽

Dorit Fabricius ◽

...

Keyword(s):

Immune Response ◽

Humoral Immune Response ◽

Age Groups ◽

Asymptomatic Infection ◽

Pseudotyped Virus ◽

Serological Response ◽

Vaccination Programs ◽

Humoral Immune ◽

Antibody Assays ◽

Human Coronaviruses

AbstractThe quality and persistence of children’s humoral immune response following SARS-CoV-2 infection remains largely unknown but will be crucial to guide pediatric SARS-CoV-2 vaccination programs. Here, we examine 548 children and 717 adults within 328 households with at least one member with a previous laboratory-confirmed SARS-CoV-2 infection. We assess serological response at 3–4 months and 11–12 months after infection using a bead-based multiplex immunoassay for 23 human coronavirus antigens including SARS-CoV-2 and its Variants of Concern (VOC) and endemic human coronaviruses (HCoVs), and additionally by three commercial SARS-CoV-2 antibody assays. Neutralization against wild type SARS-CoV-2 and the Delta VOC are analysed in a pseudotyped virus assay. Children, compared to adults, are five times more likely to be asymptomatic, and have higher specific antibody levels which persist longer (96.2% versus 82.9% still seropositive 11–12 months post infection). Of note, symptomatic and asymptomatic infections induce similar humoral responses in all age groups. SARS-CoV-2 infection occurs independent of HCoV serostatus. Neutralization responses of children and adults are similar, although neutralization is reduced for both against the Delta VOC. Overall, the long-term humoral immune response to SARS-CoV-2 infection in children is of longer duration than in adults even after asymptomatic infection.

Download Full-text

Characterization of the Humoral Immune Response Induced after Infection with Atypical Porcine Pestivirus (APPV)

Viruses ◽

10.3390/v11100880 ◽

2019 ◽

Vol 11 (10) ◽

pp. 880 ◽

Cited By ~ 4

Author(s):

Gökce Nur Cagatay ◽

Denise Meyer ◽

Michael Wendt ◽

Paul Becher ◽

Alexander Postel

Keyword(s):

Immune Response ◽

Humoral Immune Response ◽

Neutralizing Antibodies ◽

Neutralizing Antibody ◽

Humoral Immune ◽

Neutralizing Capacity ◽

Antibody Titers ◽

Antibody Levels ◽

Congenital Tremor

Atypical porcine pestivirus (APPV) is a widely distributed pathogen causing congenital tremor (CT) in piglets. So far, no data are available regarding the humoral immune response against APPV. In this study, piglets and their sows from an affected herd were tested longitudinally for viral genome and antibodies. APPV genome was detected in the majority of the piglets (14/15) from CT affected litters. Transient infection of gilts was observed. Kinetics of Erns- and E2-specific antibodies and their neutralizing capacity were determined by recently (Erns) and newly (E2) developed antibody ELISAs and virus neutralization assays. Putative maternally derived antibodies (MDA) were detected in most piglets, but displayed only low to moderate neutralizing capacity (ND50 ≤ 112). Horizontal APPV transmission occurred when uninfected and infected piglets were mingled on the flat deck. Horizontally infected piglets were clinically inapparent and showed only transient viremia with subsequently consistently high E2 antibody levels. For piglets from CT affected litters, significantly lower neutralizing antibody titers were observed. Results indicate that E2 represents the main target of neutralizing antibodies. Characterization of the humoral immune response against APPV will help to provide valuable serological diagnosis, to understand the epidemiology of this novel pathogen, and to implement tailored prevention strategies.

Download Full-text

The Local and Systemic Humoral Immune Response Against Homologous and Heterologous Strains of the Type 2 Porcine Reproductive and Respiratory Syndrome Virus

Frontiers in Immunology ◽

10.3389/fimmu.2021.637613 ◽

2021 ◽

Vol 12 ◽

Author(s):

Andrew R. Kick ◽

Amanda F. Amaral ◽

Alba Frias-De-Diego ◽

Lizette M. Cortes ◽

Jonathan E. Fogle ◽

...

Keyword(s):

Immune Response ◽

Humoral Immune Response ◽

Respiratory Syndrome Virus ◽

Post Inoculation ◽

Significant Finding ◽

Live Virus ◽

Humoral Immune ◽

Viral Shedding ◽

Iga Response

The humoral immune response plays a crucial role in the combat and protection against many pathogens including the economically most important, highly prevalent, and diverse pig pathogen PRRSV – the Porcine Reproductive and Respiratory Syndrome Virus. In addition to viremia and viral shedding analyses, this study followed the local and systemic humoral immune response of pigs for 63 days upon inoculation with one of three types of Type-2 PRRSV (PRRSV-2) strains – one modified live virus (MLV) vaccine strain, and two lineage 1 PRRSV-2 strains, NC134 and NC174. The local response was analyzed by quantifying immunoglobulin (Ig)A in nasal swabs. The systemic response was studied by the quantification of IgG with ELISA and homo- and heterologous neutralizing antibodies (NAs) utilizing a novel method of flow cytometry. In all PRRSV-2 inoculated groups, viral nasal shedding started at 3 dpi, peaked between 3 and 7 days post inoculation, and was cleared at 28–35 dpi with sporadic rebounds thereafter. The local IgA response started 4–7 days after viral shedding occurred and showed a bi-phasic course with peaks at 14 dpi and at 28–35 dpi. Of note, the NC134 and NC174 strains induced a much stronger local IgA response. As reported earlier, main viremia lasted from 7 dpi to 28 dpi (NC174), 42 dpi (NC134) or until the end of the study (MLV). Similar to the local IgA response, the systemic IgG response started 4–7 days after viremia; but in contrast to viremia, serum IgG levels stayed high for all PRRSV-2 inoculated groups until the end of the study. A significant finding was that while the serum NA response in the MLV group was delayed by 28 days, serum NAs in pigs infected with our two NC134 and NC174 strains could be detected as early as 7 dpi (NC134) and 14 dpi (NC174). Compared to homologous NA responses, the NA responses against heterologous strains was strong but slightly delayed between our lineage 1 one strains or non-existent between the MLV and lineage 1 strains. This study improves our understanding of the relationship between local and systemic infections and the humoral immune response induced by PRRSV-2 infection or MLV vaccination. Our data also provide novel insights into the timeline of the development of homologous and heterologous NA levels – by both MLV vaccination or infection with two strains from the currently prevalent PRRSV-2 lineage 1.

Download Full-text

Immune Response in Rabbits to Surface Components of Extracellular and Intracellular Forms of Vaccinia Virus

Infection and Immunity ◽

10.1128/iai.29.3.846-852.1980 ◽

1980 ◽

Vol 29 (3) ◽

pp. 846-852

Author(s):

N. Balachandran ◽

P. Seth ◽

L. N. Mohapatra

Keyword(s):

Immune Response ◽

Humoral Immune Response ◽

Peripheral Blood ◽

Surface Proteins ◽

Migration Inhibition ◽

Live Virus ◽

Humoral Immune ◽

Dependent Cell ◽

Lymphocyte Cytotoxicity ◽

Infected Cells

The development of cellular as well as humoral immune response to extracellular and intracellular forms of vaccinia virus (ECV and ICV, respectively) and their surface antigens were studied in rabbits. Direct lymphocyte cytotoxicity and peripheral blood leukocyte migration inhibition tests were used to measure cell-mediated immune response, while neutralizing and hemagglutination-inhibiting antibodies were assayed for measuring humoral immune response. Direct cytotoxicity of lymphocytes from rabbits immunized with ECV or its surface proteins was demonstrable by day 7 after immunization, and by the end of week 3 it almost declined to pre-immunization levels. Inoculation with ICV or its surface proteins failed to induce lymphocyte cytotoxicity. In contrast, migration inhibition of peripheral blood leukocytes from rabbits immunized with ECV, ICV, or their surface proteins was observed with homologous antigens. However, leukocytes from rabbits immunized with ECV or its surface proteins also showed migration inhibition in the presence of ICV. Similarly, in the humoral immune response, neutralizing antibodies were produced against homologous as well as heterologous forms of virus despite immunization with purified preparations of ECV, ICV, or their surface proteins. Adsorption with purified ICV preparations abolished the neutralizing activity of these antisera against heterologous forms of virus. Hemagglutination-inhibiting antibodies, on the other hand, were produced only after immunization with ECV or its surface proteins. In addition, antibody-dependent cell-mediated cytotoxicity was employed to detect specific antibody response after immunization of rabbits with live virus, ECV, and ICV. Antisera raised against ECV or live virus supported antibody-dependent cell-mediated cytotoxicity, whereas ICV-antiserum failed to do so. The antibody activity present in the former antisera was abolished by absorption with cell membranes from vaccinia-infected cells but not with purified ICV. The data suggest that immunization with inactivated ECV seems to bring about interaction between host immune response (cellular and humoral) and virus-infected cells, which may, perhaps, be necessary for protection against pox virus infection. A similar interaction is unlikely to occur after immunization with inactivated ICV.

Download Full-text